J. Pfefen

Most-cited papers

1. Absorption and disposition of moclobemide in patients with advanced age or reduced liver or kidney function

   K. Stoeckel, J. Pfefen, M. Mayersohn, M. Schoerlin +4 more

   1990Acta Psychiatrica Scandinavica Supplementum62 citations

   Semantic Scholar

   Save

2. Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, Parkinson's disease.

   P. Limousin, P. Pollak, J. Pfefen, C. Tournier-Gervason +2 more

   1995Clinical neuropharmacology43 citations

   Semantic Scholar

   Save

3. Pharmacokinetics of moclobemide after single and multiple oral dosing with 150 milligrams 3 times daily for 15 days

   T. Guentert, G. Tucker, A. Korn, J. Pfefen +2 more

   1990Acta Psychiatrica Scandinavica Supplementum28 citations

   Semantic Scholar

   Save

4. Cimetidine alters the disposition kinetics of the monoamine oxidase‐A inhibitor moclobemide

   M. Schoerlin, M. Mayersohn, B. Hoevels, H. Eggers +2 more

   1991Clinical pharmacology and therapy24 citations

   Semantic Scholar

   Save

5. Effect of food intake on the relative bioavailability of moclobemide (Ro 11-1163).

   M. Schoerlin, M. Mayersohn, B. Hoevels, H. Eggers +2 more

   1988Journal of neural transmission. Supplementum11 citations

   Semantic Scholar

   Save

6. Mixed linear and non-linear disposition of lazabemide, a reversible and selective inhibitor of monoamine oxidase B.

   Theodor W. Guentert, N. Holford, J. Pfefen, J. Dingemanse

   1994British Journal of Clinical Pharmacology6 citations Open access

   Semantic Scholar

   Save

7. Pharmacokinetics of moclobemide (Ro 11-1163) in patients with liver cirrhosis

   M. Schoerlin, M. Mayersohn, K. Hoffmann, E. Ohnhaus +3 more

   19882 citations

   Semantic Scholar

   Save

8. Mixedlinear andnon-linear disposition oflazabemide, a reversible andselective inhibitor ofmonoamine oxidase B

   T. Guentert, N. Holford, J. Pfefen, J. Dingemanse +1 more

   19940 citations

   Semantic Scholar

   Save